Rhythm Pharmaceuticals, Inc.
HealthcareNASDAQ:RYTM · NASDAQ Global Market
+$0.72 today
Vol 0.55M · Avg 0.80M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-141.3%
avg -97.3%
ROIC
-50.1%
avg -80.3%
ROA
-40.8%
avg -57.7%
Analysis
ROA is currently the strongest return metric at -40.8% versus its period average of -57.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David Meeker | Chairman, President & Chief Executive Officer | $1.58M | — | 72 | $107,850.00 | 0.16% |
Yann Mazabraud | Executive Vice President & Head of International | $972,148.00 | — | 53 | $10,375.00 | 0.02% |
Hunter C. Smith | Chief Financial Officer & Treasurer | $892,477.00 | — | 57 | $119,611.00 | 0.17% |
Jennifer Lee | Executive Vice President & Head of North America | $838,635.00 | — | 51 | $32,500.00 | 0.05% |
Alastair Garfield | Chief Scientific Officer | $806,385.00 | — | 46 | $25,000.00 | 0.04% |
Joseph Shulman | Chief Technical Officer | $734,854.00 | — | 51 | $22,500.00 | 0.03% |
Pamela J. Cramer | Chief Human Resources Officer | — | — | 52 | $17,500.00 | 0.03% |
Sarah Ryan | Vice President of Sales & Marketing | — | — | — | — | — |
Jim Flaherty | Senior Vice President & General Counsel | — | — | — | — | — |
Elisabeth Cronert-Bendell | Senior Vice President & Head of Strategy | — | — | — | — | — |
Christopher German | Corporate Controller & Principal Accounting Officer | — | — | 54 | $2,701.00 | <0.01% |
David Connolly | Head of Investor Relations & Corporate Communications | — | — | — | $107,850.00 | 0.16% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
53
$20.33M
Net Sentiment
$20.33M
Net selling
Most Active
Smith Hunter C
28 transactions
1–10 of 53
Analysis
Insiders reported 0 buys worth $0.00 and 53 sells worth $20.33M over the last 12 months. That adds up to net selling of $20.33M. Smith Hunter C was the most active insider with 28 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.71B
Nuvalent, Inc.
NASDAQ:NUVL
$9.07B
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
$7.06B
Arcellx, Inc.
ACLX
$6.73B
Akero Therapeutics, Inc.
AKRO
$4.50B
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
$3.90B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.59B
Stoke Therapeutics, Inc.
NASDAQ:STOK
$1.86B
uniQure N.V.
NASDAQ:QURE
$1.74B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.62B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.47B
Ventyx Biosciences, Inc.
VTYX
$1.00B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
$841.97M
Solid Biosciences Inc.
NASDAQ:SLDB
$556.28M
Arvinas, Inc.
NASDAQ:ARVN
$489.07M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$300.28M
Inozyme Pharma, Inc.
INZY
$258.25M
Atrium Therapeutics, Inc.
NASDAQ:RNA
$211.60M
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
$100.28M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$69.97M
Who manages RYTM?
Rhythm Pharmaceuticals, Inc. (RYTM) lists 12 active executives. The top listed executive is Hunter C. Smith, Chief Financial Officer & Treasurer.
Are RYTM insiders buying or selling?
Recent insider activity shows net buying of $3.73M.
Explore More
Continue the stock analysis
Jump to another research area for this company.